Brodowicz T, Koestler W J, Tomek S, Vaclavik I, Herscovici V, Wiltschke C, Steger G G, Zielinski C C
Department of Medicine I, University Hospital, Vienna, Austria.
Anticancer Drugs. 2000 Mar;11(3):149-53. doi: 10.1097/00001813-200003000-00002.
Nineteen breast cancer patients pretreated with one or two anthracycline-containing regimens for visceral metastases received i.v. docetaxel 100 mg/m2 on day 1, q 21d. Docetaxel was administered as second-line therapy in 11 patients, whereas eight patients received docetaxel in a third-line setting. In the second-line setting, complete response (CR) was achieved in two (18%), partial response (PR) in four (36%) and stable disease (SD) in three (27%) patients resulting in a response rate (RR) of 54%. In the third-line setting three (38%) patients experienced PR (RR 38%) and two (25%) SD. In the second-line setting, median time to progression was 6.5+/-3.9 months (range 2.1-15.8) versus 4.7+/-5.5 months (range 0.6-15.9) in the third-line setting. Median overall survival was 9.6+/-8.0 months (range 2.7-25.8) versus 11.2-6.1 months (range 4.8-18.7). Overall, no patient experienced treatment-limiting toxicities. We conclude that docetaxel induced responses in 48% of anthracycline-resistant patients enrolled into the present study. The safety profile of docetaxel was manageable and tolerable. Docetaxel represented efficacious treatment in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.
19例因内脏转移接受过一或两种含蒽环类方案预处理的乳腺癌患者，于第1天静脉注射多西他赛100mg/m²，每21天一次。11例患者将多西他赛作为二线治疗，而8例患者在三线治疗时接受多西他赛治疗。在二线治疗中，2例（18%）患者达到完全缓解（CR），4例（36%）患者部分缓解（PR），3例（27%）患者疾病稳定（SD），缓解率（RR）为54%。在三线治疗中，3例（38%）患者出现PR（RR 38%），2例（25%）患者疾病稳定。在二线治疗中，至疾病进展的中位时间为6.5±3.9个月（范围2.1 - 15.8个月），而在三线治疗中为4.7±5.5个月（范围0.6 - 15.9个月）。中位总生存期为9.6±8.0个月（范围2.7 - 25.8个月），而在三线治疗中为11.2 - 6.1个月（范围4.8 - 18.7个月）。总体而言，无患者出现治疗限制性毒性。我们得出结论，多西他赛使本研究中48%的蒽环类耐药患者产生反应。多西他赛的安全性可控且可耐受。对于尽管先前接受过含蒽环类化疗但仍进展的转移性乳腺癌患者，多西他赛是一种有效的治疗方法。
